Carlos Alban net worth and biography

Carlos Alban Biography and Net Worth

Vice Chairman of AbbVie
Carlos Alban is Vice Chairman, Chief Commercial Officer of the Company. Mr. Alban is AbbVie's Executive Vice President, Commercial Operations. He served as Abbott's Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial Operations from 2011 to 2012, as Senior Vice President, International Pharmaceuticals from 2009 to 2011, as Vice President, Western Europe and Canada from 2007 to 2009, and as Vice President, European Operations from 2006 to 2007. Mr. Alban joined Abbott in 1986.

What is Carlos Alban's net worth?

The estimated net worth of Carlos Alban is at least $18.56 million as of July 7th, 2020. Mr. Alban owns 137,899 shares of AbbVie stock worth more than $18,555,689 as of September 30th. This net worth approximation does not reflect any other assets that Mr. Alban may own. Learn More about Carlos Alban's net worth.

What is Carlos Alban's salary?

As the Vice Chairman of AbbVie Inc., Mr. Alban earned a total compensation package of $16,853,926.00 in 2020. Mr. Alban earned a salary of $1,211,808.00, stock awards of $5,822,401.00, options awards of $1,390,831.00, non-equity compensation of $2,475,000.00, and other compensation of $324,644.00. Learn More on Carlos Alban's salary.

How do I contact Carlos Alban?

The corporate mailing address for Mr. Alban and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Carlos Alban's contact information.

Has Carlos Alban been buying or selling shares of AbbVie?

Carlos Alban has not been actively trading shares of AbbVie in the last ninety days. Most recently, Carlos Alban sold 53,325 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $100.00, for a transaction totalling $5,332,500.00. Following the completion of the sale, the insider now directly owns 137,899 shares of the company's stock, valued at $13,789,900. Learn More on Carlos Alban's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 17 times. They sold a total of 1,048,944 shares worth more than $146,558,841.47. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Carlos Alban Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/7/2020Sell53,325$100.00$5,332,500.00137,899View SEC Filing Icon  
3/1/2018Sell83,574$114.49$9,568,387.26133,026View SEC Filing Icon  
6/14/2017Sell45,800$70.00$3,206,000.00160,545View SEC Filing Icon  
5/4/2017Sell43,000$67.00$2,881,000.00114,745View SEC Filing Icon  
5/10/2016Sell47,438$63.52$3,013,261.76149,444View SEC Filing Icon  
3/3/2014Sell2,882$50.09$144,359.38205,138View SEC Filing Icon  
See Full Table

Carlos Alban Buying and Selling Activity at AbbVie

This chart shows Carlos Alban's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $134.21
Low: $134.09
High: $142.33

50 Day Range

MA: $141.00
Low: $134.21
High: $151.15

2 Week Range

Now: $134.21
Low: $106.86
High: $175.91

Volume

15,336,473 shs

Average Volume

6,873,221 shs

Market Capitalization

$237.30 billion

P/E Ratio

19.01

Dividend Yield

3.95%

Beta

0.72